Objective: Neutrophil to lymphocyte ratio (NLR) is a recently popular diagnostic marker. We sought answers to questions such as whether this marker has a role in the diagnosis of prostate cancer, any cut off value can be calculated, compa- red to platelet lymphocyte ratio (PLR) and it has a relationship with Gleason score and percentage of tumors detected in biopsy cores. In addition, we aimed to share the findings of patients undergoing transrectal ultrasound (TRUS) guided biopsy.
Materials and Methods: The results of 679 patients who underwent TRUS-guided prostate biopsy with prostate specific antigen (PSA) va- lues above 2.5 ng / ml in our clinic between Au- gust 2014 and February 2017 were retrospectively analyzed. Patients were between 2.5-3.9 ng / ml (Group 1), 4-9.9 ng / ml (Group 2), 10-19.9 ng / ml (Group 3), 20 ng / ml and above (Group 4) ac- cording to PSA values, divided into four groups. The diagnostic value of NLR was evaluated in the- se groups.
Results: NLR was found as a diagnostic mar- ker in groups 2,3 and 4. The cut off value was cal- culated as 2.5. It had similar diagnostic power as PLR. There was a poor correlation with Gleason score and percentage of tumor in cores. It was not important in predicting bone metastasis. The dif- ference between PSA density and DRE was statis- tically significant in groups with pathologic pros- tate cancer (PCa) or benign prostatic hyperplasia (BPH).
Conclusion: Although NLR is not very strong in the diagnosis of PCa, it has a diagnostic value. It can be used as a marker to support PSA.
Keywords: Neutrophil lymphocyte ratio (NLR), prostate cancer, diagnostic marker.
Abstract
Objective: Neutrophil to lymphocyte ratio (NLR) is a recently popular diagnostic marker. We sought answers to questions such as whether this marker has a role in the diagnosis of prostate cancer, any cut off value can be calculated, compa- red to platelet lymphocyte ratio (PLR) and it has a relationship with Gleason score and percentage of tumors detected in biopsy cores. In addition, we aimed to share the findings of patients undergoing transrectal ultrasound (TRUS) guided biopsy.
Materials and Methods: The results of 679 patients who underwent TRUS-guided prostate biopsy with prostate specific antigen (PSA) va- lues above 2.5 ng / ml in our clinic between Au- gust 2014 and February 2017 were retrospectively analyzed. Patients were between 2.5-3.9 ng / ml (Group 1), 4-9.9 ng / ml (Group 2), 10-19.9 ng / ml (Group 3), 20 ng / ml and above (Group 4) ac- cording to PSA values, divided into four groups. The diagnostic value of NLR was evaluated in the- se groups.
Results: NLR was found as a diagnostic mar- ker in groups 2,3 and 4. The cut off value was cal- culated as 2.5. It had similar diagnostic power as PLR. There was a poor correlation with Gleason score and percentage of tumor in cores. It was not important in predicting bone metastasis. The dif- ference between PSA density and DRE was statis- tically significant in groups with pathologic pros- tate cancer (PCa) or benign prostatic hyperplasia (BPH).
Conclusion: Although NLR is not very strong in the diagnosis of PCa, it has a diagnostic value. It can be used as a marker to support PSA.
Keywords: Neutrophil lymphocyte ratio (NLR), prostate cancer, diagnostic marker.